Меню
Набор скоро начнётся NCT07696897

Procalcitonin Versus Serum Zinc for Diagnosis of Ventilator-Associated Pneumonia in ICU Patients

Наблюдательное Ventilator Acquired Pneumonia

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Serum Procalcitonin Measurement, Serum Zinc Measurement.
Кому может быть актуально
Состояния в реестре: Ventilator Acquired Pneumonia. Базовые параметры: 18 лет — 70 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Египет
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Comparative Diagnostic Accuracy of Procalcitonin Versus Serum Zinc as Biomarkers for the Diagnosis of Ventilator Acquired Pneumonia in Adults Admitted to the ICU

Обзор

Ventilator-associated pneumonia (VAP) is a common and serious infection among mechanically ventilated ICU patients. Early diagnosis remains challenging because clinical and radiological findings may lack specificity. Procalcitonin (PCT) is a well-established biomarker of bacterial infection, while serum zinc has recently emerged as a potential marker of immune dysfunction and infection severity. This prospective observational cohort study will compare the diagnostic accuracy of serum procalcitonin and serum zinc for the diagnosis of ventilator-associated pneumonia in 84 adult ICU patients. Diagnostic performance will be assessed using ROC curve analysis, sensitivity, specificity, positive predictive value, and negative predictive value. Associations between biomarker levels, inflammatory markers, disease severity scores, and clinical outcomes will also be evaluated.

Подробное описание

Ventilator-associated pneumonia (VAP) is a major healthcare-associated infection that develops in patients receiving invasive mechanical ventilation for at least 48 hours. It is associated with prolonged intensive care unit (ICU) stay, increased healthcare costs, greater need for organ support, and increased mortality. Despite advances in critical care, accurate and timely diagnosis of VAP remains challenging because clinical and radiological criteria alone may lack sufficient specificity.

Procalcitonin (PCT) is a well-established biomarker that rises in response to bacterial infections and has been used to support diagnosis, assess disease severity, and guide antibiotic therapy. Zinc is an essential trace element involved in immune regulation, inflammatory response, antioxidant defense, and maintenance of epithelial barrier integrity. Zinc deficiency is common among critically ill patients and has been associated with increased susceptibility to infection and poorer clinical outcomes.

This prospective observational cohort study will be conducted in the Intensive Care Unit of Sohag University Hospital. Eighty-four adult mechanically ventilated ICU patients with suspected ventilator-associated pneumonia will be enrolled. Clinical assessment, laboratory investigations, microbiological cultures, chest imaging, and severity scoring systems including SOFA and CURB-65 will be performed according to the study protocol.

Serum procalcitonin and serum zinc levels will be measured at the time of VAP suspicion and repeated after 72 hours. Blood cultures and respiratory samples will be obtained whenever possible before initiation of antibiotic therapy. Patients will be followed throughout their ICU stay to evaluate disease progression and clinical outcomes.

The primary objective of the study is to compare the diagnostic accuracy of serum procalcitonin and serum zinc for confirmed ventilator-associated pneumonia using receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) measurements.

Secondary objectives include comparison of sensitivity, specificity, positive predictive value, and negative predictive value of both biomarkers at predefined cutoff values; evaluation of the diagnostic performance of a combined biomarker model; assessment of correlations between biomarker levels and inflammatory markers such as C-reactive protein and white blood cell count; and evaluation of associations between biomarker levels, disease severity scores, duration of mechanical ventilation, length of ICU stay, and 28-day mortality.

Вмешательства

  • Диагностический тест Serum Procalcitonin Measurement
    Measurement of serum procalcitonin levels for evaluation of diagnostic accuracy in ventilator-associated pneumonia.
  • Диагностический тест Serum Zinc Measurement
    Measurement of serum zinc levels for evaluation of diagnostic accuracy in ventilator-associated pneumonia.

Первичные конечные точки

  • Diagnostic accuracy (AUC) of serum procalcitonin versus serum zinc for identification of bacterial pneumonia [Срок оценки: At presentation (baseline)]
Вторичные конечные точки (3)
  • Sensitivity and specificity of serum procalcitonin and serum zinc [Срок оценки: At presentation (baseline)]
  • Positive predictive value and negative predictive value of serum procalcitonin and serum zinc [Срок оценки: At presentation (baseline)]
  • Diagnostic performance of combined serum procalcitonin and serum zinc model [Срок оценки: At presentation (baseline)]

Критерии участия

Критерии включения

  • \- Age 18 to 70 years.
  • Adult patients admitted to the Intensive Care Unit.
  • Receiving invasive mechanical ventilation for at least 48 hours.
  • Clinical suspicion of ventilator-associated pneumonia (VAP).
  • New or progressive pulmonary infiltrate on chest imaging.
  • At least two of the following:
  • Fever >38°C or hypothermia <36°C.
  • Leukocytosis (>12,000/mm³) or leukopenia (<4,000/mm³).
  • Purulent tracheal secretions.
  • Worsening oxygenation or increased ventilatory requirements.
  • Written informed consent obtained from the patient or legally authorized representative.

Критерии исключения

  • \- Age less than 18 years or greater than 70 years.
  • Known chronic liver disease.
  • End-stage renal disease requiring dialysis.
  • Immunocompromised patients (including HIV infection, chemotherapy, organ transplantation, or long-term immunosuppressive therapy).
  • Current zinc supplementation or known disorders of zinc metabolism.
  • Hematologic malignancies.
  • Autoimmune diseases requiring immunosuppressive treatment.
  • Active non-pulmonary bacterial infection requiring systemic antibiotic therapy.
  • Chronic inflammatory diseases that may affect serum zinc levels.
  • Pregnancy.
  • Refusal or inability to provide informed consent.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Египет · 1 центр
  • Sohag University Hospital — Sohag

Публикации

  • Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011 Sep 22;9:107. doi: 10.1186/1741-7015-9-107. PMID 21936959
  • Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014 Jul;34(4):263-73. doi: 10.3343/alm.2014.34.4.263. Epub 2014 Jun 19. PMID 24982830
  • Prasad AS. Zinc in human health: effect of zinc on immune cells. Mol Med. 2008 May-Jun;14(5-6):353-7. doi: 10.2119/2008-00033.Prasad. PMID 18385818
  • Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020 May;46(5):888-906. doi: 10.1007/s00134-020-05980-0. Epub 2020 Mar 10. PMID 32157357
  • Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008 Mar;36(3):941-52. doi: 10.1097/CCM.0B013E318165BABB. PMID 18431284

Идентификаторы

NCT: NCT07696897 · Soh-Med--26-6-2MD

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗